Nektar Therapeutics ( (NKTR) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nektar Therapeutics shares are climbing after the company unveiled strong Phase 2b results for its lead immunology drug, rezpegaldesleukin, at the 2026 American Academy of Dermatology meeting. The treatment showed promising benefits for patients with atopic dermatitis and alopecia areata, which is boosting investor confidence in the drug’s commercial potential.
Analysts are responding to the positive data and the decision to move rezpegaldesleukin into Phase 3 trials by raising their price targets, adding further fuel to the rally. The stock’s rise is occurring despite newly filed securities class-action lawsuits tied to earlier trial enrollment issues, which so far appear to be taking a back seat to the upbeat clinical outlook.
More about Nektar Therapeutics
YTD Price Performance: 70.18%
Average Trading Volume: 1,114,694
Technical Sentiment Signal: Hold
Current Market Cap: $2.06B
For further insights into NKTR stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.